EGFR and neoplasm: In squamous cell carcinoma of head and neck (SCCHN) cells, we have recently demonstrated that the clinically approved HDACi vorinostat enhanced the antitumoral effects of the EGFR-TKI gefitinib, by a mechanism depending on the ErbB3 status and on the tumor cell phenotype (epithelial vs. mesenchymal).